Dr. Chavez Mac Gregor on Key Results From SWOG S1207 in HR+/HER2- Breast Cancer

In Partnership With:

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Mariana Chavez Mac Gregor, MD, MSC, associate professor, Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial (NCT01674140) of everolimus (Afinitor) in hormone receptor (HR)–positive, HER2-negative breast cancer.

This randomized, placebo-controlled trial investigated the role of the addition of the mTOR-inhibitor everolimus plus standard adjuvant endocrine therapy in high-risk patients, Chavez Mac Gregor begins. Patients were randomly assigned 1:1 to either the investigator’s choice of adjuvant endocrine therapy plus 1 year of everolimus or placebo. The trial’s primary end point was invasive disease-free survival (IDFS), with secondary end points including overall survival (OS) and safety. Subset analyses included a preplanned evaluation according to risk group and exploratory analyses of menopausal status and age.

Final analysis by risk group revealed that everolimus elicited no improvement in survival outcomes among postmenopausal patients, Chavez Mac Gregor states. However, an exploratory analysis of 581 premenopausal patients did show a statistically significant increase in both IDFS and OS, Chavez Mac Gregor says. Despite the negative outcome of this study, these data were thought-provoking and hypothesis-generating, she emphasizes.

Safety data showed that patients treated with everolimus also experienced a higher rate of grade 3 and 4 adverse events (AEs) compared with patients in the control group, Chavez Mac Gregor continues. Moreover, the treatment discontinuation rate was higher in the experimental arm due to treatment-related adverse events, she states. These results signify the need for improved understanding of the drug’s toxicity profile, tolerability, and AE management in this patient population, Chavez Mac Gregor explains. Future research should aim to address the low completion rate and high toxicity associated with everolimus.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content